Patents Examined by Maher M. Haddad
  • Patent number: 11945858
    Abstract: The present disclosure concerns antibodies specific for the Na v.7 polypeptides which are capable of antagonizing the biological activity of the Na v.7 polypeptide. The anti-Na v.7 antibodies can be used for alleviating the symptoms of pain and/or for treating or alleviating the symptoms of an hyperproliferative disease. The presence disclosure also concerns immunogens and methods for making antibodies, such as the anti-Na v.7 antibodies, comprising a single-domain antibody.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: April 2, 2024
    Assignee: NATIONAL RESEARCH COUNCIL OF CANADA
    Inventors: Marzia Martina, Balu Chakravarthy, Yves Durocher, Mehdi Arbabi-Ghahroudi, Anne Marcil, Danica Stanimirovic, Traian Sulea, Maria Moreno, Umberto Banderali
  • Patent number: 11933786
    Abstract: Antibodies that selectively bind to glycosylated PD-1 relative to unglycosylated PD-1 are provided. In some aspects, PD-1 polypeptides comprising glycosylated amino acid positions are also provided. Methods for making and using such antibodies and polypeptides (e.g., for the treatment of cancer) are also provided.
    Type: Grant
    Filed: November 13, 2020
    Date of Patent: March 19, 2024
    Assignees: STCUBE, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS
    Inventors: Stephen S. Yoo, Ezra M. Chung, Yong-Soo Kim, Mien-Chie Hung, Chia-Wei Li, Seung-Oe Lim
  • Patent number: 11932680
    Abstract: Fibronectin type III domains (FN3) that specifically bind to CD8A, related polynucleotides capable of encoding CD8A-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, and detectably labeled FN3 domains are useful in therapeutic and diagnostic applications.
    Type: Grant
    Filed: March 8, 2022
    Date of Patent: March 19, 2024
    Assignee: Janssen Biotech, Inc.
    Inventors: Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
  • Patent number: 11912760
    Abstract: Described herein are doppel-targeting molecules (e.g., antibodies) useful for inhibiting pathological angiogenesis and treating diseases and conditions associated with pathological angiogenesis, such as tumors, cancers, atherosclerosis, tuberculosis, asthma, pulmonary arterial hypertension (PAH), neoplasms and neoplasm-related conditions, and for detecting doppel expression in a subject. Related compositions and methods also are described.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: February 27, 2024
    Assignee: PHAROSGEN CO., LTD
    Inventors: Youngro Byun, Ha Kyeong Lee, So Young Choi, So Ra Park, Se Ra Lee, Seung Il Baek
  • Patent number: 11911468
    Abstract: A method of treating pulmonary metastasis of osteosarcoma cells (pOSs) in a subject in need thereof includes administering to the subject a therapeutically effective amount of an agent that interferes with VCAM-1/?4?1 signaling between pOSs expressing VCAM-1 and pulmonary macrophages (MACs) expressing ?4?1.
    Type: Grant
    Filed: May 4, 2021
    Date of Patent: February 27, 2024
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Alex Yee-Chen Huang, Jay T. Myers
  • Patent number: 11897946
    Abstract: Disclosed herein are Complement factor H (CFH) inhibitors, such as anti-CFH antibodies and small molecules, and methods of using said inhibitors.
    Type: Grant
    Filed: August 26, 2021
    Date of Patent: February 13, 2024
    Assignee: Duke University
    Inventors: Edward F. Patz, Jr., Michael J. Campa, Elizabeth Gottlin, Barton F. Haynes, Hua-Xin Liao, M. Anthony Moody
  • Patent number: 11884731
    Abstract: A method for treating a human patient suffering from fistulizing Crohn's disease, comprising administering to a patient suffering from fistulizing Crohn's disease, a humanized antibody having binding specificity for human ?4?7 integrin, wherein the human patient has a seton that was surgically placed prior to administration of the antibody, and wherein the dosing regimen induces fistula(e) healing.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: January 30, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventor: Karen L. Lasch
  • Patent number: 11884726
    Abstract: The present invention provides a method for the treatment of a patient comprising administering to the patient an initial dose of between about 1 mg and about 150 mg of a MAdCAM antagonist antibody. Biomarkers for assessing a patient's response to anti-MAdCAM treatment are also provided.
    Type: Grant
    Filed: November 30, 2020
    Date of Patent: January 30, 2024
    Assignee: Pfizer Inc.
    Inventors: Fabio Cataldi, Robert A. Clare, Gail M. Comer, Vivekananda Pradhan, Alaa Ahmad, Mina Hassan-Zahraee, Mera Krishnan Tilley, Weidong Zhang, Anindita Banerjee, Karen Michelle Page, Michael Steven Vincent, David J. Von Schack
  • Patent number: 11873348
    Abstract: The present invention relates to novel bispecific polypeptides, such as antibodies, and their use in the treatment of cancers, particularly cancers expressing carcinoembryonic antigen (CEA).
    Type: Grant
    Filed: November 4, 2022
    Date of Patent: January 16, 2024
    Assignee: ALLIGATOR BIOSCIENCE AB
    Inventors: Peter Ellmark, Karin Hagerbrand, Laura Varas, Mattias Levin, Anna Säll, Laura von Schantz
  • Patent number: 11872288
    Abstract: The present invention relates to immunoconjugates, compositions, methods and uses for treating brain tumors, especially glioma, by administration of a tumour necrosis factor alpha (TNF?) immunoconjugate.
    Type: Grant
    Filed: May 24, 2021
    Date of Patent: January 16, 2024
    Inventor: Theresa Hemmerle
  • Patent number: 11866497
    Abstract: The present invention provides an antibody to a fibrosis-related molecule and medical application thereof. The antibody of the present invention is an antibody that binds to CHL1 protein and an antibody that neutralizes the binding of the CHL1 protein to a fibroblast.
    Type: Grant
    Filed: August 11, 2021
    Date of Patent: January 9, 2024
    Assignee: The University of Tokyo
    Inventors: Yosuke Kurashima, Hiroshi Kiyono
  • Patent number: 11858979
    Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
    Type: Grant
    Filed: February 16, 2021
    Date of Patent: January 2, 2024
    Assignee: Bristol-Meyers Squibb Company
    Inventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
  • Patent number: 11858984
    Abstract: Provided is a substance capable of effectively suppressing cancer metastasis or a pharmaceutical composition that effectively acts on an inflammatory disease. The pharmaceutical composition is a pharmaceutical composition containing, as an active ingredient, an antibody or an antibody fragment thereof having antigen-binding activity for an S100A8/A9 heterodimer, and blocks interaction between S100A8/A9 and a group of receptors therefor, to thereby strongly suppress cancer metastasis both in vitro and in vivo, or alleviate inflammation. That is, the anti-S100A8/A9 antibody or the antibody fragment thereof can strongly suppress cancer metastasis or alleviate inflammation, by virtue of its blocking action on the interaction between S100A8/A9 and the group of receptors therefor.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: January 2, 2024
    Assignees: National University Corporation Okayama University, Niigata University, National University Corporation Gunma University
    Inventors: Masakiyo Sakaguchi, Shinichi Toyooka, Shuta Tomida, Kazuhiko Shien, Hiroki Sato, Rie Kinoshita, Junichiro Futami, Kota Araki, Mikio Okazaki, Eisaku Kondo, Yusuke Inoue, Akira Yamauchi
  • Patent number: 11845790
    Abstract: The present disclosure relates to SH3YL1 monoclonal antibodies and compositions comprising the SH3YL1 monoclonal antibodies. The disclosure also relates to isolated nucleic acid molecules encoding the SH3YL1 antibodies, vectors comprising the nucleic acid molecules, and host cells comprising the vectors. Also disclosed are methods of modulating an immune response, methods of treating diabetic nephropathy, and methods of treating non-alcoholic steatosis hepatitis comprising administering the SH3YL1 antibodies. Also disclosed are methods of treating acute kidney injury and methods of treating inflammatory bowel disease comprising administering the SH3YL1 antibodies.
    Type: Grant
    Filed: September 14, 2021
    Date of Patent: December 19, 2023
    Assignee: Celros Biotech
    Inventors: Yun Soo Bae, Eunjung An, Jung-Yeon Yoo, Hyunbo Shim, Hye Eun Lee
  • Patent number: 11834512
    Abstract: In certain aspects, provided herein are inhibitory anti-ENPP1 antibodies and antigen binding fragments thereof. In some aspects, provided herein are methods of treating myocardial infarction using the antibodies provided herein. In certain aspects, provided herein are nucleic acid molecules encoding the antibodies provided herein, host cells comprising such nucleic acids, and methods of making the antibodies provided herein using such host cells. In some aspects, also provided herein are pharmaceutical compositions comprising the antibodies provided herein.
    Type: Grant
    Filed: May 3, 2021
    Date of Patent: December 5, 2023
    Assignee: The Regents of the University of California
    Inventor: Arjun Deb
  • Patent number: 11814426
    Abstract: There is provided antibodies or antigen-binding fragments, derivatives or variants thereof which are capable of binding to the FBG domain of tenascin-C. There are also provided uses of such antibodies or antigen-binding fragments, derivatives or variants thereof, as well as methods of identifying such antibodies.
    Type: Grant
    Filed: April 13, 2021
    Date of Patent: November 14, 2023
    Inventors: Kim Suzanne Midwood, Philip Antony Bland-Ward, Nigel Burns, Patrick John Hextall, Susan Rebecca Aungier
  • Patent number: 11807684
    Abstract: Humanized or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to and neutralize human CD47, and find use in various therapeutic methods. Preferred are non-activating antibodies. Embodiments of the invention include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the humanized or chimeric anti-CD47 monoclonal antibodies; and cell lines that produce these monoclonal antibodies. Also provided are amino acid sequences of the antibodies.
    Type: Grant
    Filed: April 21, 2021
    Date of Patent: November 7, 2023
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jie Liu, Irving L. Weissman, Ravindra Majeti
  • Patent number: 11802156
    Abstract: The present disclosure relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to MAdCAM, preferably human MAdCAM and that function to inhibit MAdCAM. The disclosure also relates to human anti-MAdCAM antibodies and antigen-binding portions thereof. The disclosure also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The disclosure also relates to isolated heavy and light chain immunoglobulins derived from human anti-MAdCAM antibodies and nucleic acid molecules encoding such immunoglobulins. The present disclosure also relates to methods of making human anti-MAdCAM antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The disclosure also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-MAdCAM antibodies.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: October 31, 2023
    Assignee: Pfizer Inc.
    Inventor: Karin Anderson
  • Patent number: 11795221
    Abstract: Provided are novel fully human monoclonal antibodies that bind to human LAG-3. It also provides the methods of hybridoma generation using humanized rats, the nucleic acid molecules encoding the anti-LAG-3 antibodies, expression vectors and host cells used for the expression of anti-LAG-3 antibodies. The invention further provides the methods for validating the function of antibodies in vitro. The antibodies of invention provide a potent agent for the treatment of multiple cancers via modulating human immune function.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: October 24, 2023
    Assignee: WUXI BIOLOGICS IRELAND LIMITED
    Inventors: Yong Zheng, Qiong Wu, Jing Li
  • Patent number: 11795238
    Abstract: High affinity antibodies capable of binding to a single-chain variable fragment (scFv) of anti-CD70 antibody, for example, the scFv expressed on cell surface as a portion of a chimeric antigen receptor (CAR). Also provided herein are methods for producing such anti-scFv antibodies and methods of using the antibodies disclosed herein for detecting, for example, T cells expressing an anti-CD70 CAR that comprise the scFv as an extracellular domain.
    Type: Grant
    Filed: August 3, 2021
    Date of Patent: October 24, 2023
    Assignee: CRISPR Therapeutics AG
    Inventors: Lalit Kumar, Mary-Lee Dequeant